Abstract

A Pooled Overall Survival (OS) Analysis of 5-Year Data from the COMFORT-I and COMFORT-II Trials of Ruxolitinib for the Treatment of Myelofibrosis (MF)

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase (JAK) Inhibitor
John Mascarenhas ... Srdan Verstovsek
Blood | VOL. 136
John Mascarenhas, et. al.John Mascarenhas ... Srdan Verstovsek
05 Nov 2020
A Pooled Overall Survival Analysis of The COMFORT Studies: 2 Randomized Phase 3 Trials of Ruxolitinib For The Treatment of Myelofibrosis
Alessandro M Vannucchi ... Srdan Verstovsek
Blood | VOL. 122
Alessandro M Vannucchi, et. al.Alessandro M Vannucchi ... Srdan Verstovsek
07 Jul 2021
A Randomized, Phase 3 Trial of Fedratinib Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Previously Treated with Ruxolitinib (FREEDOM2)
Nicola Vianelli ... Francesco Passamonti
Blood | VOL. 138
Nicola Vianelli, et. al.Nicola Vianelli ... Francesco Passamonti
05 Nov 2021
Long-Term Efficacy and Safety in COMFORT-II, a Phase 3 Study Comparing Ruxolitinib with Best Available Therapy for the Treatment of Myelofibrosis: 5-Year Final Study Results
Claire N Harrison ... Tiziano Barbui
Blood | VOL. 126
Claire N Harrison, et. al.Claire N Harrison ... Tiziano Barbui
03 Dec 2015
View more papers

More From: Blood

Paper Title
Journal
Date
Author
JAK2/mTOR Inhibition Fails to Prevent Acute GVHD Despite Reduced Th1/Th17 cells: Final Phase II Trial Results.
Joseph A Pidala ... Brian C Betts
Blood | VOL. -
Joseph A Pidala, et. al.Joseph A Pidala ... Brian C Betts
24 Jul 2024
Critical Role of Tripartite Fusion and LBD Truncation in Certain RARA- and all RARG-Related Atypical APL.
Xiaosu Zhou ... Hongxing Liu
Blood | VOL. -
Xiaosu Zhou, et. al.Xiaosu Zhou ... Hongxing Liu
24 Jul 2024
Ruxolitinib for pediatric patients with treatment-naïve and steroid-refractory acute graft-versus-host disease (REACH4).
Franco Locatelli ... Christina Diaz-De-Heredia
Blood | VOL. -
Franco Locatelli, et. al.Franco Locatelli ... Christina Diaz-De-Heredia
24 Jul 2024
A predictive model for therapy failure in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor therapy.
Xiaoshuai Zhang ... Qian Jiang
Blood | VOL. -
Xiaoshuai Zhang, et. al.Xiaoshuai Zhang ... Qian Jiang
24 Jul 2024
View more papers